Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Biotechnology company Regeneron will acquire ... Regeneron assured 23andMe's 15 million customers that their data—including genetic and health information, genealogy, and other sensitive ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

A biotech company has announced plans to acquire 23andMe after the genetic testing company filed for Chapter 11 bankruptcy.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...